AI Article Synopsis
- Liver fibrosis and biological sex influence the likelihood of developing hepatocellular carcinoma (HCC) and extrahepatic cancers (EHCs) in people with metabolic dysfunction-associated steatotic liver disease (MASLD).
- The differences in cancer risk based on these factors suggest the need for tailored chemoprevention and precision medicine strategies in treating MASLD.
- This understanding calls for more research to explore how these variables can inform better treatment approaches.
Article Abstract
Liver fibrosis and biological sex variably modulate the risks of hepatocellular carcinoma (HCC) and extrahepatic cancers (EHCs) arising in the context of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we highlight how these variables may have implications in the setting of chemoprevention and precision medicine approaches in MASLD and guide additional research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tem.2024.12.009 | DOI Listing |
Publication Analysis
Top Keywords
metabolic dysfunction-associated
8
dysfunction-associated steatotic
8
steatotic liver
8
liver disease
8
widening horizons
4
horizons metabolic
4
disease cancer
4
cancer liver
4
liver fibrosis
4
fibrosis biological
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!